FWD Group Holdings Limited (“FWD Group” or “FWD”) announced it has signed a cooperation agreement with Roche Diagnostics Asia Pacific Pte Ltd (“Roche”) to leverage Roche’s navify® digital healthcare solutions and advanced diagnostic methodologies for innovation in FWD’s health insurance services in Asia.
The collaboration will span an initial period of three years. It aims to bring to market health solutions at the forefront of modern medicine and healthcare to improve health outcomes for FWD’s customers in a cost-effective way.
Binayak Dutta, Managing Director of FWD Group, said “At FWD, we believe that shifting the emphasis from a reactive to a proactive healthcare model is critical to giving our customers the best opportunity to celebrate living. The integration of advanced diagnostics technology into the healthcare ecosystem can improve patient outcomes in ways that we’ve never seen before.”
In May, FWD Group announced the introduction of FWD HealthyMe, a new health business unit. FWD HealthyMe aims to develop innovative partnerships with healthcare providers and industry leaders and be a trusted proactive health partner to customers in Asia. It builds on the strong foundations provided by FWD’s suite of life insurance, critical illness, and medical offerings.
Dr. Sarah Salvilla, Group Chief Health Officer of FWD Group, said “By working with Roche, we aim to accelerate health insurance innovation in Asia as part of our vision of changing the way people feel about insurance. Roche is a recognized leader in diagnostics, having delivered 29 billion tests last year alone globally, and we’re delighted to partner with them.”
navify® digital solutions from Roche Diagnostics are designed to transform laboratory and clinical data into actionable insights, delivering operational and financial value, and helping to personalize care along each individual healthcare journey.
Lance Little, Managing Director of Roche Diagnostics Asia Pacific, said, “We are delighted to collaborate with FWD Group to develop opportunities for early diagnosis to their customers, leveraging the latest research and technology. Earlier diagnoses lead to better health outcomes and insights that can lead to behavior and lifestyle changes, which can keep a person healthy and out of the hospital. Others might reveal an imminent threat and lead to a life-saving decision.”
The agreement between FWD Group and Roche is expected to be activated progressively in selected FWD markets in the coming months.
Manuel “Jumbing” De Rosas, CEO & President of FWD Philippines, said, “This partnership is a significant step in bringing advanced, diagnostic-driven healthcare solutions to our customers. When the partnership is being activated in the Philippines, we are optimistic it will further elevate our customer care by providing reliable, trustworthy, and accessible health resources to more Filipinos, contributing to nation-building as they celebrate living and build their best future.”